Why outdated paper prescribing information is creating unnecessary cost, complexity and friction across a modern pharmaceutical supply chain.
News|Articles|August 3, 2026
FAQ: Pharma's July 31 Tariff Deadline Has Passed. Now What?
Author(s)Stephen Appezzato
The Section 232 tariff deadline for 17 major drugmakers has arrived. Here's what pharma supply chain teams need to know now.
Advertisement
Advertisement
The Section 232 pharmaceutical tariff regime is no longer a future date on the calendar. As of July 31, 2026, it's active law for the industry's largest manufacturers, with a second deadline and a separate generics timeline still ahead. Here's what changed and what to watch next.
Related to this article
Foreign-trade zones allow pharma companies to hold imported inventory closer to U.S. demand while deferring duties and keeping market allocation open.
BMS’s Kevin Cook explains why digital capability is becoming a must-have for strategic CMO partners and why the next phase starts with the basics.
Episode 4 of Supply Chain Signal examines PhRMA’s legal challenge to CMS’ GLOBE model and whether manufacturers can lower costs, expand U.S. production and strengthen supply chain resilience all at once.
At LogiPharma USA 2026, BMS’s Kevin Cook explains why CMO partnerships must move beyond transactions toward shared goals and KPIs.
Octapharma USA's Kerem Tokel, a LogiPharma USA 2026 freight security panelist, discusses theft hotspots, the export of stolen pharmaceutical loads and how to tighten chain of custody.
The rule targets PBMs, but rebate, price protection and formulary deals they strike with drugmakers will be disclosed to plan fiduciaries and open to audit.
DOL's final rule requires PBMs to disclose rebates and formulary incentives to large self-insured plans for plan years beginning on or after July 1, 2027.
Advertisement
Advertisement